Trial Design of PCSK9-inhibitor, Evolocumab, in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
June 18, 2018
In this video, Prof Paul Maruff discusses a recently published paper which details the design of a study investigating the PCSK9-inhibitor, evolocumab, in pediatric patients with heterozygous familial hypercholesterolemia. The FDA has been investigating reports of cognitive impairment associated with the use of lipid-lowering medications for several years, and while they did not link statins […]
Structured Exercise Program Improves Cognitive Functioning for Patients with First-Episode Psychosis
June 6, 2018
While exercise is a proven partner in good brain health, its benefits are now being studied in more specific neurological disorders. Swedish and Australian researchers recently published a new study on the effects of an organized exercise program on a group of adults diagnosed with first-episode psychosis. Results showed a positive relationship between exercise and […]
Study Shows Similar Symptom Profile in Ketamine Dependence with Persistent Psychosis and Schizophrenia
March 28, 2018
Researchers measured psychosis (PANSS) and cognitive impairments (Cogstate), and the symptom profile of persisting psychosis due to chronic heavy ketamine abuse resembled that of schizophrenia Enormous interest has recently been focused on a potential role for ketamine in treating depression. A non-opioid anesthetic with a long track record, ketamine may now present an entirely new […]
Studies Show Healthy Lifestyle Program Can Slow Cognitive Decline
February 11, 2018
As we age, a healthy lifestyle becomes more important to not only keep our body in shape but also to protect our brain from decline. Previous studies have shown that nutrition, physical workouts and cognitive exercise can benefit both our muscles and our mind. For the brain, a proactive daily program can slow the effects […]
Strategic Central Monitoring of Psychometric Tests and Rating Scales
January 17, 2018
Even when employing the most intensive rater training program, many raters may still make errors in administering and scoring some psychometric tests and rating scales in clinical trials. Cogstate Central Monitoring helps ensure the highest possible data quality through rigorous expert review — acting as an extension of the rater training program. Our central monitoring […]
Stay Hydrated Throughout The Day For Better Cognitive Performance
January 10, 2018
Right up there with taking ten thousand daily steps, drinking enough water is another recommended health goal to include in your New Year’s resolutions. While many of us try to maintain our weekly average hydration through the foods and beverages we consume, there can be fluctuations throughout each day, caused by our work or exercise […]
Key Advantages of Computerized Cognitive Testing in Clinical Trials
December 6, 2017
Cogstate computerized cognitive tests have been designed and validated to withstand the numerous operational challenges of conducting clinical trials — dramatically increasing the sensitivity and specificity of the measurement of cognition in clinical research. The tests are highly standardized for non-expert administration, rapid and repeatable with limited learning effect, and the novel stimuli and translations […]
Cogstate Participation at CTAD 2017
November 20, 2017
In this video Cogstate CSO, Prof Paul Maruff, discusses the recent Clinical Trials in Alzheimer’s Disease (CTAD) conference and the exciting scientific contributions from Cogstate, as featured in the following presentations: Use of the International Shopping List Test as the objective assessment of cognitive impairment to identify subjects with early Alzheimer’s disease in the Eisai […]
The International Shopping List Test in Alzheimer’s Disease Clinical Trials
October 19, 2017
Objective cognitive impairment typical of Alzheimer’s disease can be established using episodic memory tests, and word list learning tests are a type of episodic memory test commonly used. The Cogstate International Shopping List Test (ISLT) is a word list learning test that has several advantages for sensitively measuring episodic memory in global clinical trials, including […]
Key Takeaways from the 2017 National Alzheimer’s Summit
October 12, 2017
By 2050, more than 13 million Americans are estimated to be living with Alzheimer’s disease, and the costs of care is expected to mount to over a trillion dollars. In this video, Cogstate CEO, Brad O’Connor, discusses key takeaways from his experience presenting at the National Alzheimer’s Summit hosted by UsAgainstAlzheimer’s. He heard perspectives from […]
Subject Eligibility Review and Diagnostic Adjudication
September 22, 2017
When inappropriate subjects are enrolled into a clinical trial, the success of the study can be at risk. Sponsors seek to protect the integrity of their study by identifying subjects who violate the protocol, and preventing them from being inappropriately randomized to treatment. Dr. Edward Bartolic, Senior Scientific Director at Cogstate, gives an overview and […]
